Sodium-glucose cotransporter 2 (SGLT2) inhibitors (eg, canagliflozin, dapagliflozin, empagliflozin) lower serum glucose in patients with diabetes but also induce diuresis by increasing natriuresis and glycosuria without significantly affecting serum electrolytes (1 - 4).